130 related articles for article (PubMed ID: 16818517)
1. Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
Yoon KJ; Qi J; Remack JS; Virga KG; Hatfield MJ; Potter PM; Lee RE; Danks MK
Mol Cancer Ther; 2006 Jun; 5(6):1577-84. PubMed ID: 16818517
[TBL] [Abstract][Full Text] [Related]
2. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
3. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
Wierdl M; Tsurkan L; Hyatt JL; Edwards CC; Hatfield MJ; Morton CL; Houghton PJ; Danks MK; Redinbo MR; Potter PM
Cancer Gene Ther; 2008 Mar; 15(3):183-92. PubMed ID: 18188187
[TBL] [Abstract][Full Text] [Related]
4. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.
Danks MK; Morton CL; Krull EJ; Cheshire PJ; Richmond LB; Naeve CW; Pawlik CA; Houghton PJ; Potter PM
Clin Cancer Res; 1999 Apr; 5(4):917-24. PubMed ID: 10213229
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.
Danks MK; Yoon KJ; Bush RA; Remack JS; Wierdl M; Tsurkan L; Kim SU; Garcia E; Metz MZ; Najbauer J; Potter PM; Aboody KS
Cancer Res; 2007 Jan; 67(1):22-5. PubMed ID: 17210679
[TBL] [Abstract][Full Text] [Related]
6. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.
Yoon KJ; Hyatt JL; Morton CL; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2004 Aug; 3(8):903-9. PubMed ID: 15299073
[TBL] [Abstract][Full Text] [Related]
7. In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy.
Shabat D; Lode HN; Pertl U; Reisfeld RA; Rader C; Lerner RA; Barbas CF
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7528-33. PubMed ID: 11404472
[TBL] [Abstract][Full Text] [Related]
8. Human neural stem cell tropism to metastatic breast cancer.
Zhao D; Najbauer J; Annala AJ; Garcia E; Metz MZ; Gutova M; Polewski MD; Gilchrist M; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2012 Feb; 30(2):314-25. PubMed ID: 22084033
[TBL] [Abstract][Full Text] [Related]
9. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11.
Meck MM; Wierdl M; Wagner LM; Burger RA; Guichard SM; Krull EJ; Harris LC; Potter PM; Danks MK
Cancer Res; 2001 Jul; 61(13):5083-9. PubMed ID: 11431345
[TBL] [Abstract][Full Text] [Related]
10. Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
Pawlik CA; Iyengar RV; Krull EJ; Mason SE; Khanna R; Harris LC; Potter PM; Danks MK; Guichard SM
Mol Ther; 2000 May; 1(5 Pt 1):457-63. PubMed ID: 10933967
[TBL] [Abstract][Full Text] [Related]
11. Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.
Oosterhoff D; Witlox MA; van Beusechem VW; Haisma HJ; Schaap GR; Bras J; Kruyt FA; Molenaar B; Boven E; Wuisman PI; Pinedo HM; Gerritsen WR
Mol Cancer Ther; 2003 Aug; 2(8):765-71. PubMed ID: 12939466
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
Danks MK; Morton CL; Pawlik CA; Potter PM
Cancer Res; 1998 Jan; 58(1):20-2. PubMed ID: 9426050
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of subdural medulloblastomas using human neural stem cells expressing carboxylesterase.
Lim SH; Choi SA; Lee JY; Wang KC; Phi JH; Lee DH; Song SH; Song JH; Jin X; Kim H; Lee HJ; Lim I; Kim SU; Kim SK
Cancer Gene Ther; 2011 Nov; 18(11):817-24. PubMed ID: 21869821
[TBL] [Abstract][Full Text] [Related]
14. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.
Stubdal H; Perin N; Lemmon M; Holman P; Bauzon M; Potter PM; Danks MK; Fattaey A; Dubensky T; Johnson L
Cancer Res; 2003 Oct; 63(20):6900-8. PubMed ID: 14583489
[TBL] [Abstract][Full Text] [Related]
15. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
Matzow T; Cowen RL; Williams KJ; Telfer BA; Flint PJ; Southgate TD; Saunders MP
J Gene Med; 2007 Apr; 9(4):244-52. PubMed ID: 17397102
[TBL] [Abstract][Full Text] [Related]
17. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.
Wierdl M; Wall A; Morton CL; Sampath J; Danks MK; Schuetz JD; Potter PM
Mol Pharmacol; 2003 Aug; 64(2):279-88. PubMed ID: 12869632
[TBL] [Abstract][Full Text] [Related]
18. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.
Senter PD; Beam KS; Mixan B; Wahl AF
Bioconjug Chem; 2001; 12(6):1074-80. PubMed ID: 11716702
[TBL] [Abstract][Full Text] [Related]
19. Enzyme-prodrug systems: carboxylesterase/CPT-11.
Danks MK; Potter PM
Methods Mol Med; 2004; 90():247-62. PubMed ID: 14657567
[No Abstract] [Full Text] [Related]
20. Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.
Hyatt JL; Tsurkan L; Wierdl M; Edwards CC; Danks MK; Potter PM
Mol Cancer Ther; 2006 Sep; 5(9):2281-8. PubMed ID: 16985062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
